Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $7.50.

GANX has been the topic of several research reports. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Wednesday, July 1st. Oppenheimer reiterated an “outperform” rating on shares of Gain Therapeutics in a research note on Wednesday, May 27th. Wall Street Zen raised shares of Gain Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, June 21st. Roth Capital reaffirmed a “buy” rating on shares of Gain Therapeutics in a report on Tuesday, May 12th. Finally, BTIG Research restated a “buy” rating and issued a $5.00 target price on shares of Gain Therapeutics in a research report on Tuesday, June 30th.

Gain Therapeutics Stock Down 3.8%

Shares of NASDAQ:GANX opened at $1.75 on Tuesday. The firm has a market cap of $74.64 million, a PE ratio of -3.02 and a beta of 0.15. The company has a fifty day simple moving average of $1.79 and a 200 day simple moving average of $1.97. The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.02. Gain Therapeutics has a 12-month low of $1.41 and a 12-month high of $4.34.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13). During the same period last year, the firm posted ($0.16) EPS. On average, equities research analysts anticipate that Gain Therapeutics will post -0.54 EPS for the current fiscal year.

Institutional Trading of Gain Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Potomac Capital Management Inc. acquired a new stake in Gain Therapeutics in the fourth quarter worth approximately $3,252,000. JPMorgan Chase & Co. bought a new stake in Gain Therapeutics in the third quarter worth about $47,000. Apollon Wealth Management LLC bought a new position in shares of Gain Therapeutics during the 4th quarter valued at about $64,000. Oliver Luxxe Assets LLC acquired a new position in shares of Gain Therapeutics in the 4th quarter worth approximately $65,000. Finally, Engineers Gate Manager LP acquired a new stake in Gain Therapeutics during the fourth quarter valued at approximately $47,000. 11.97% of the stock is currently owned by institutional investors.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.